NCT07042685 2026-04-09
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
Clinical Trials
30 trialsNCT07136077 2026-04-06
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07011576 2026-03-18
FRUITFUL
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT07392346 2026-02-11
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07270991 2026-02-05
FRUQUITAS
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT05954429 2026-01-22
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Fudan University
Phase 2 Recruiting
NCT06856837 2025-12-12
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07130903 2025-11-10
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting
NCT06441565 2025-07-30
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University
Phase 2/3 Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05771181 2025-06-12
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Fudan University
Phase 2 Recruiting
NCT07003022 2025-06-04
Phase â…¡ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
Phase 2 Recruiting
NCT06980532 2025-05-20
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Tongji Hospital
Phase 1/2 Recruiting
NCT05941325 2025-05-18
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT06791083 2025-01-24
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2 Recruiting
NCT06427005 2025-01-22
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
West China Hospital
Phase 2 Recruiting
NCT06417892 2025-01-14
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
NCT06446154 2024-12-31
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06714903 2024-12-04
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
The First Hospital of Jilin University
Recruiting
NCT06685276 2024-11-20
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06646588 2024-10-17
SJZ-RMEEC01
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06551207 2024-08-13
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Tongji Hospital
Phase NA Recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06234007 2024-03-18
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06168786 2023-12-21
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06091423 2023-11-30
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06118762 2023-11-07
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
The First Affiliated Hospital of Nanchang University
Phase 4 Recruiting
NCT06102785 2023-10-26
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Recruiting
NCT06018714 2023-08-31
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study
Sun Yat-sen University
Phase 2 Recruiting